aficamten

Aficamten is an **oral, selective small-molecule cardiac myosin inhibitor** developed by Cytokinetics for hypertrophic cardiomyopathy. It acts directly on the cardiac sarcomere to reduce pathologic hypercontractility, lower left ventricular outflow tract gradients, and improve symptoms and exercise capacity in patients with hypertrophic cardiomyopathy, especially obstructive disease. The asset has been described as a next-in-class cardiac myosin inhibitor and has been developed globally by Cytokinetics, with regional commercialization collaborations including Bayer in Japan and rights in Greater China that were previously licensed to Corxel and later transferred to Sanofi. Public sources indicate U.S. approval under the brand name Myqorzo for adults with symptomatic obstructive hypertrophic cardiomyopathy, while additional development has included non-obstructive and pediatric hypertrophic cardiomyopathy programs.

Brand names

Myqorzo

Other names

aficamtenBAY3723113BAY-3723113BAY 3723113CK 3773274CK3773274CK-3773274CK-274CK274CK 274